Olema Pharmaceuticals Statistics
Share Statistics
Olema Pharmaceuticals has 57.30M shares outstanding. The number of shares has increased by 4.56% in one year.
| Shares Outstanding | 57.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 49.58M |
| Failed to Deliver (FTD) Shares | 2.74K |
| FTD / Avg. Volume | 0.46% |
Short Selling Information
The latest short interest is 8.31M, so 14.5% of the outstanding shares have been sold short.
| Short Interest | 8.31M |
| Short % of Shares Out | 14.5% |
| Short % of Float | 16.76% |
| Short Ratio (days to cover) | 24.76 |
Valuation Ratios
The PE ratio is -6.57 and the forward PE ratio is -4.37.
| PE Ratio | -6.57 |
| Forward PE | -4.37 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.5 |
| P/FCF Ratio | -7.58 |
| PEG Ratio | n/a |
Enterprise Valuation
Olema Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 12.33, with a Debt / Equity ratio of 0.
| Current Ratio | 12.33 |
| Quick Ratio | 12.33 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.39 |
| Cash Flow / Debt | -84.74 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.38% and return on capital (ROIC) is -40.95%.
| Return on Equity (ROE) | -0.38% |
| Return on Assets (ROA) | -0.35% |
| Return on Capital (ROIC) | -40.95% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.31M |
| Employee Count | 74 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -45% in the last 52 weeks. The beta is 2.03, so Olema Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 2.03 |
| 52-Week Price Change | -45% |
| 50-Day Moving Average | 10.73 |
| 200-Day Moving Average | 11.6 |
| Relative Strength Index (RSI) | 26.71 |
| Average Volume (20 Days) | 591.10K |
Income Statement
In the last 12 months, Olema Pharmaceuticals had revenue of $0 and earned -$96.66M in profits. Earnings per share was $-2.14.
| Revenue | 0 |
| Gross Profit | -377.00K |
| Operating Income | -104.96M |
| Net Income | -96.66M |
| EBITDA | -104.58M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.14 |
Balance Sheet
The company has $68.54M in cash and $2.42M in debt, giving a net cash position of $66.12M.
| Cash & Cash Equivalents | 68.54M |
| Total Debt | 2.42M |
| Net Cash | 66.12M |
| Retained Earnings | -305.63M |
| Total Assets | 230.17M |
| Working Capital | 187.29M |
Cash Flow
In the last 12 months, operating cash flow was -$83.73M and capital expenditures $0, giving a free cash flow of -$83.73M.
| Operating Cash Flow | -83.73M |
| Capital Expenditures | 0 |
| Free Cash Flow | -83.73M |
| FCF Per Share | -1.85 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
OLMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -31.89% |
| FCF Yield | -21.79% |
Analyst Forecast
The average price target for OLMA is $27, which is 302.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $27 |
| Price Target Difference | 302.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 5.84 |
| Piotroski F-Score | 2 |